JP2016501213A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501213A5 JP2016501213A5 JP2015544557A JP2015544557A JP2016501213A5 JP 2016501213 A5 JP2016501213 A5 JP 2016501213A5 JP 2015544557 A JP2015544557 A JP 2015544557A JP 2015544557 A JP2015544557 A JP 2015544557A JP 2016501213 A5 JP2016501213 A5 JP 2016501213A5
- Authority
- JP
- Japan
- Prior art keywords
- negative
- breast cancer
- pharmaceutical composition
- subject
- her2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010038795 estrogen receptors Proteins 0.000 claims description 24
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 21
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 21
- 108090000468 progesterone receptors Proteins 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 10
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 4
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 4
- 229940123237 Taxane Drugs 0.000 claims description 4
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 4
- 229960004117 capecitabine Drugs 0.000 claims description 4
- 229960000575 trastuzumab Drugs 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims 28
- 208000026310 Breast neoplasm Diseases 0.000 claims 27
- 102000015694 estrogen receptors Human genes 0.000 claims 23
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 102000003998 progesterone receptors Human genes 0.000 claims 16
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 claims 13
- 229960003649 eribulin Drugs 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 238000000034 method Methods 0.000 claims 11
- 238000011269 treatment regimen Methods 0.000 claims 9
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 6
- 206010038111 Recurrent cancer Diseases 0.000 claims 5
- 230000000306 recurrent effect Effects 0.000 claims 5
- 238000000338 in vitro Methods 0.000 claims 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 238000001815 biotherapy Methods 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 201000007280 estrogen-receptor negative breast cancer Diseases 0.000 claims 1
- 229940125697 hormonal agent Drugs 0.000 claims 1
- 229960000908 idarubicin Drugs 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100025803 Progesterone receptor Human genes 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229960000439 eribulin mesylate Drugs 0.000 description 1
- QAMYWGZHLCQOOJ-PWIVHLLHSA-N eribulin mesylate Chemical compound CS(O)(=O)=O.C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 QAMYWGZHLCQOOJ-PWIVHLLHSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261733238P | 2012-12-04 | 2012-12-04 | |
| US61/733,238 | 2012-12-04 | ||
| US201361878204P | 2013-09-16 | 2013-09-16 | |
| US61/878,204 | 2013-09-16 | ||
| PCT/IB2013/002911 WO2014087230A1 (en) | 2012-12-04 | 2013-12-04 | Use of eribulin in the treatment of breast cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019002177A Division JP6678783B2 (ja) | 2012-12-04 | 2019-01-09 | 乳がんの処置におけるエリブリンの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016501213A JP2016501213A (ja) | 2016-01-18 |
| JP2016501213A5 true JP2016501213A5 (https=) | 2018-05-31 |
| JP6466339B2 JP6466339B2 (ja) | 2019-02-06 |
Family
ID=50031376
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015544557A Active JP6466339B2 (ja) | 2012-12-04 | 2013-12-04 | 乳がんの処置におけるエリブリンの使用 |
| JP2019002177A Active JP6678783B2 (ja) | 2012-12-04 | 2019-01-09 | 乳がんの処置におけるエリブリンの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019002177A Active JP6678783B2 (ja) | 2012-12-04 | 2019-01-09 | 乳がんの処置におけるエリブリンの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20140163095A1 (https=) |
| EP (1) | EP2928464A1 (https=) |
| JP (2) | JP6466339B2 (https=) |
| KR (1) | KR20150090921A (https=) |
| AU (2) | AU2013353745A1 (https=) |
| BR (1) | BR112015012731A2 (https=) |
| CA (1) | CA2892780A1 (https=) |
| IL (1) | IL239007B (https=) |
| MX (1) | MX2015007185A (https=) |
| RU (1) | RU2689977C2 (https=) |
| WO (1) | WO2014087230A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2522663T1 (sl) | 2004-06-03 | 2015-08-31 | Eisai R&D Management Co., Ltd. | Vmesne spojine za pripravo halihondrina B |
| CN102369008B (zh) | 2009-03-30 | 2014-10-29 | 卫材R&D管理有限公司 | 脂质体组合物 |
| MY162940A (en) | 2009-08-19 | 2017-07-31 | Eisai R&D Man Co Ltd | Quinoline derivative-containing pharmaceutical composition |
| JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| RU2689977C2 (ru) * | 2012-12-04 | 2019-05-30 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Применение эрибулина для лечения рака молочной железы |
| JP6644479B2 (ja) * | 2014-06-24 | 2020-02-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | がん治療のための併用療法としてのエリブリンとｓ−１（もしくは５−ｆｕ）の使用 |
| PT3524595T (pt) | 2014-08-28 | 2022-09-19 | Eisai R&D Man Co Ltd | Derivado de quinolina altamente puro e método para produção do mesmo |
| LT3263106T (lt) | 2015-02-25 | 2024-01-10 | Eisai R&D Management Co., Ltd. | Chinolino darinių kartumo sumažinimo būdas |
| AU2016226157B2 (en) * | 2015-03-04 | 2022-01-27 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and eribulin for treating cancer |
| MX373231B (es) | 2015-06-16 | 2020-05-08 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
| US12220398B2 (en) | 2015-08-20 | 2025-02-11 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| WO2017188350A1 (ja) | 2016-04-28 | 2017-11-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍の成長を抑制する方法 |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| EP3582804A1 (en) * | 2017-02-20 | 2019-12-25 | Polyphor Ag | Pharmaceutical combinations for treating cancer |
| RU2019134940A (ru) | 2017-05-16 | 2021-06-16 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Лечение гепатоцеллюлярной карциномы |
| US20200129473A1 (en) * | 2017-07-21 | 2020-04-30 | Eisai R&D Management Co., Ltd. | Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer |
| WO2019097073A1 (en) | 2017-11-20 | 2019-05-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| CN111918667A (zh) * | 2018-02-05 | 2020-11-10 | 特沙诺有限公司 | 儿科尼拉帕尼配制剂和儿科治疗方法 |
| JP2021517135A (ja) * | 2018-03-09 | 2021-07-15 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | 化学療法抵抗性がんの組合せ処置 |
| CN113271977A (zh) * | 2018-11-09 | 2021-08-17 | G1治疗公司 | 使用艾日布林和选择性cdk4/6抑制剂组合治疗癌症的治疗方案 |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| WO2025106586A1 (en) * | 2023-11-13 | 2025-05-22 | Luxvitae Therapeutics Inc. | Macrocyclic ketone compounds and applications thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6653341B1 (en) | 1998-06-17 | 2003-11-25 | Eisai Co., Ltd. | Methods and compositions for use in treating cancer |
| JP4454151B2 (ja) | 1998-06-17 | 2010-04-21 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 大環状類似体及びそれらの使用並びに調製方法 |
| SI2522663T1 (sl) | 2004-06-03 | 2015-08-31 | Eisai R&D Management Co., Ltd. | Vmesne spojine za pripravo halihondrina B |
| KR20070114753A (ko) * | 2005-02-18 | 2007-12-04 | 아브락시스 바이오사이언스 인크. | 치료제의 조합 및 투여 방식, 및 조합 요법 |
| BRPI0709075A2 (pt) * | 2006-03-20 | 2011-10-11 | Medigene Ag | tratamento de cáncer de mama triplo receptor negativo |
| BRPI0817909B1 (pt) | 2007-10-03 | 2022-06-21 | Eisai R&D Management Co., Ltd | Métodos de obtenção e de preparação de uma composição diastereomericamente pura, compostos, e método para produzir os referidos compostos |
| CA2720632C (en) | 2008-04-04 | 2016-12-20 | Eisai R&D Management Co., Ltd. | Halichondrin b analogs |
| RU2579511C2 (ru) | 2010-01-26 | 2016-04-10 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Производные фуро[3,2-в]пирана, применимые в синтезе аналогов |
| EP2686441B1 (en) * | 2011-03-18 | 2019-05-08 | Eisai R&D Management Co., Ltd. | Methods and uses for predicting response to eribulin |
| RU2689977C2 (ru) * | 2012-12-04 | 2019-05-30 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Применение эрибулина для лечения рака молочной железы |
-
2013
- 2013-12-04 RU RU2015126539A patent/RU2689977C2/ru active
- 2013-12-04 WO PCT/IB2013/002911 patent/WO2014087230A1/en not_active Ceased
- 2013-12-04 KR KR1020157017971A patent/KR20150090921A/ko not_active Ceased
- 2013-12-04 AU AU2013353745A patent/AU2013353745A1/en not_active Abandoned
- 2013-12-04 US US14/096,827 patent/US20140163095A1/en not_active Abandoned
- 2013-12-04 CA CA2892780A patent/CA2892780A1/en not_active Abandoned
- 2013-12-04 JP JP2015544557A patent/JP6466339B2/ja active Active
- 2013-12-04 BR BR112015012731A patent/BR112015012731A2/pt not_active Application Discontinuation
- 2013-12-04 EP EP13826752.1A patent/EP2928464A1/en not_active Withdrawn
- 2013-12-04 MX MX2015007185A patent/MX2015007185A/es unknown
-
2015
- 2015-05-25 IL IL239007A patent/IL239007B/en active IP Right Grant
-
2018
- 2018-08-09 AU AU2018214086A patent/AU2018214086B2/en not_active Withdrawn - After Issue
-
2019
- 2019-01-09 JP JP2019002177A patent/JP6678783B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501213A5 (https=) | ||
| RU2015126539A (ru) | Применение эрибулина для лечения рака молочной железы | |
| Chae et al. | Repurposing metformin for cancer treatment: current clinical studies | |
| Trédan et al. | Ixabepilone alone or with cetuximab as first-line treatment for advanced/metastatic triple-negative breast cancer | |
| Guion-Dusserre et al. | FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma | |
| Velenik et al. | A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer | |
| Zhang et al. | Current landscape of personalized clinical treatments for triple-negative breast cancer | |
| RU2016151303A (ru) | Применение эрибулина в лечении рака | |
| Park et al. | Cyclophosphamide, methotrexate, and 5-fluorouracil as palliative treatment for heavily pretreated patients with metastatic breast cancer: a multicenter retrospective analysis | |
| HK1248539A1 (zh) | 借助塞里班土单抗的组合治疗 | |
| Bisagni et al. | The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer | |
| Park et al. | Treatment patterns and outcomes in elderly patients with metastatic breast cancer: a multicenter retrospective study | |
| Noomhorm et al. | In vitro and in vivo effects of xanthorrhizol on human breast cancer MCF-7 cells treated with tamoxifen | |
| Wang et al. | Application of lobaplatin in trans-catheter arterial chemoembolization for primary hepatic carcinoma | |
| Chen et al. | RC48-antibody-drug conjugate in metastatic urothelial carcinoma: A multicenter real-world study in China | |
| WO2014189937A1 (en) | Specific cancer treatment regimens with ganetespib | |
| Nemunaitis et al. | A phase I trial of oral ridaforolimus (AP23573; MK-8669) in combination with bevacizumab for patients with advanced cancers | |
| JP5889335B2 (ja) | 癌治療用医薬組成物 | |
| Piatek et al. | Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors | |
| Melcher et al. | 191 DETECT III–a Multicenter, Randomized, Phase III Study to Compare Standard Therapy Alone Versus Standard Therapy Plus Lapatinib in Patients with Initially HER2-negative Metastatic Breast Cancer and HER2-positive Circulating Tumor Cells | |
| Tsubamoto et al. | Phase II study of interval debulking surgery followed by intraperitoneal chemotherapy for advanced ovarian cancer: a Kansai Clinical Oncology Group study (KCOG9812) | |
| Sikora-Kupis et al. | First experience in treating advanced urothelial cancer with enfortumab vedotin. Single-centre retrospective study of patients qualified for a rescue access procedure | |
| US20230406931A1 (en) | Adjuvant Durvalumab in Combination with Chemotherapy for Treatment of Cancer | |
| Alsina et al. | A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients: M. Alsina et al. | |
| Ranjan et al. | Overview of Traditional Methods of Diagnosis and Treatment for Women-Associated Cancers |